drugset / Trial / NCT01876810

Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction

NCT01876810

Phase 2 Completed 28 enrolled Centre for Addiction and Mental Health
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the effect of gemfibrozil on nicotine reinforcement and cue-elicited craving. Other objectives of this study include screening for the ability of gemfibrozil to aid smoking abstinence during a brief quit attempt and examining the validity of using laboratory measures of tobacco dependence to predict smoking abstinence. It is hypothesized that gemfibrozil will result in diminished nicotine reinforcement, an attenuated response to smoking cues, and an increase in smoking abstinence compared with placebo. It is also hypothesized that the laboratory measures will prove valid in predicting abstinence.

Timeline

Start
2014-02
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemfibrozil Small molecule 600 mg

Indications